The study covers a detailed analysis segmented by key business segments i.e. by type (Sample Preparation, Platforms & Consumables, Services and Data Analysis) , by application (Cancer Biomarkers, Cancer Heterogeneity and Drug Resistance, Cancer Immune Microenvironment and Others) and major geographies.
What is NGS-Based RNA-Sequencing?
NGS-Based RNA-Sequencing is increasingly the method of choice for researchers studying the transcriptome. It offers some advantages over gene expression arrays. It is a sequencing technique that uses next-generation sequencing to reveal the presence and quantity of RNA in a biological sample at a given moment, analyzing the continuously changing cellular transcriptome. Increasing diseases like cancer and others is the major factors driving that market growth North America dominates the global NGS-Based RNA-Sequencing market.
|Unit||Value (USD Million)|
|Key Companies Profiled||Illumina (United States), Thermo Fisher Scientific (United States), BGI Genomics (China), Agilent Technologies (United States), 10X Genomics (United States), QIAGEN (Germany), GENEWIZ (United States), MACROGEN (United States), Pacific Biosciences of California (United States) and Oxford Nanopore Technologies (United States)|
The competition is expected to become even more intense in the years to come due to entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the markets competitive landscape and offers information on the products offered by various leading companies. Additionally, this NGS-Based RNA-Sequencing market analysis report suggests strategies Players can follow and recommends key areas they should focus on, in order to take maximum benefits of growth opportunities.
The report offers several leading Players, some of them are Illumina (United States), Thermo Fisher Scientific (United States), BGI Genomics (China), Agilent Technologies (United States), 10X Genomics (United States), QIAGEN (Germany), GENEWIZ (United States), MACROGEN (United States), Pacific Biosciences of California (United States) and Oxford Nanopore Technologies (United States).
In 2021, Illumina, Inc. has acquired GRAIL. The acquisition will boost access and adoption of the life-saving test worldwide. The transaction is driven by the belief that the life-saving test should be available to as many people as possible as quickly as possible.
The FDA’s proposed framework also raises concerns as to whether it effectively protects consumer safety or threatens scientific discovery and innovation. As questions about regulation, statutory power, and legislation reform remain, the FDA and healthcare leaders must consider logistical and stakeholder challenges if they seek to transform clinical care with NGS technology.
Global NGS-Based RNA-Sequencing is a fragmented market due to the presence of various players. The players are focusing on investing more in Launching New Technologies. These will enhance their market presence. The companies are also planning strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge.
Development in Portable Sequencing Technology and Rapid Advances in Genomic Technology
- High Cost Associated with the NGS-Based RNA-Sequencing
Increasing Applications of RNA-Sequencing in the Field of Cancer is creating Opportunities for the Market Growth
Key highlights of the Global NGS-Based RNA-Sequencing market Study:
CAGR of the market during the forecast period 2021-2027
In-depth information on growth factors that will accelerate the NGS-Based RNA-Sequencing market in next few years.
Detailed Insights on futuristic trends and changing consumer behaviour
Forecast of the Global NGS-Based RNA-Sequencing market size and its contribution to the parent market by type, application and by country.
A broad view of customer demand
Uncover markets competitive landscape and in-depth information on various Players
Comprehensive information about factors that will challenge the growth of NGS-Based RNA-Sequencing Players
Transformation and Important Trigegrs:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
A tipping point in globalization
A major slowdown in Western economies
Significant shifts in technology and cost structure
The challenges of regulatory compliance
New forms of competition developing
The top-down and bottom-up approaches are used to estimate and validate the size of the Global NGS-Based RNA-Sequencing market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in NGS-Based RNA-Sequencing market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes NGS-Based RNA-Sequencing Regulatory Bodies, Potential Investors, New Entrants, Research and Development Institutes and Others.
This helps us to gather the data for the players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.
Frequently Asked Questions (FAQ):1. Where the NGS-Based RNA-Sequencing industry is heading?
NGS-Based RNA-Sequencing Market is heading robustly to achieve new growth cycle.2. Is NGS-Based RNA-Sequencing market is changing from growth to value?
The Concentration Rate of Global NGS-Based RNA-Sequencing market is dominated by Players and may generate healthy valuation by 2027.
3. Who are the key players profiled in the NGS-Based RNA-Sequencing Market?
Companies that are profiled in Global NGS-Based RNA-Sequencing Market are Illumina (United States), Thermo Fisher Scientific (United States), BGI Genomics (China), Agilent Technologies (United States), 10X Genomics (United States), QIAGEN (Germany), GENEWIZ (United States), MACROGEN (United States), Pacific Biosciences of California (United States) and Oxford Nanopore Technologies (United States) etc.